title: Pulmonary complications of inflammatory myopathy.
abstract: Pulmonary complications cause significant morbidity and mortality in the idiopathic inflammatory myopathies. Advances in biomarker discovery have facilitated clinical phenotyping, allowing investigators to better define at-risk patient subsets and to potentially gauge disease activity. This serologic characterization has complemented more traditional assessment tools. Pharmacologic management continues to rely on the use of corticosteroids, often in combination with additional immunosuppressive agents. The rarity of myositis-associated interstitial lung disease and lack of controlled trials have limited analyses of treatment efficacy, mandating the development of standardized outcome measures and improvement of data sharing between disciplines.
authors.affiliation: Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Miami Miller School of Medicine, 1600 NW 10th Avenue, #1140, Miami, FL 33136, USA.
authors.forename: Shelly A
authors.initials: SA
authors.lastname: Miller
authors.affiliation: Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Miami Miller School of Medicine, 1600 NW 10th Avenue, #1140, Miami, FL 33136, USA.
authors.forename: Marilyn K
authors.initials: MK
authors.lastname: Glassberg
authors.affiliation: Division of Rheumatology, University of Miami Miller School of Medicine, Rosenstiel Medical Science Building 7152, 1600 Northwest 10th Avenue, Miami, FL 33136-1050, USA. Electronic address: dascherman@med.miami.edu.
authors.forename: Dana P
authors.initials: DP
authors.lastname: Ascherman
mesh_terms: D006801:Humans; D008171:Lung Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D017563:Lung Diseases, Interstitial / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D009220:Myositis / Q000150:complications / Q000276:immunology*
keywords: Autoantibodies; Dermatomyositis; Inflammatory myopathy; Interstitial lung disease (ILD); Polymyositis